Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

Edward B. Garon, Byoung Chul Cho, Alexander Luft, Jorge Alatorre-Alexander, Sarayut Lucien Geater, Sang‐We Kim, Grygorii Ursol, Maen Hussein, Farah Louise Lim, Cheng‐Ta Yang, Luiz H. Araujo, Haruhiro Saito, Niels Reinmuth, Nenad Medić, Helen Mann, Xiaojin Shi, Solange Peters, Tony Mok, Melissa L. Johnson